ABSTRACT. Group B streptococcal (GBS) sepsis produces arterial hypoxemia in newborns. In piglets we previously found that hypoxemia develops because of increased ventilation perfusion heterogeneity, and reduced mixed venous p 0 2 occurring in association with decreased pulmonary blood flow. We hypothesize that increased thromboxane A2 (TxA2) synthesis mediates the immediate alterations in gas exchange found in GBS sepsis. We studied 18 anesthetized, ventilated piglets before, during, and after a 30-min infusion of 2 x lo9 colony forming units/kg of GBS. Nine piglets were pretreated with 8 mg/ kg of dazmegrel (DAZ), a TxA2 synthetase inhibitor, and nine animals received GBS without DAZ pretreatment. Pulmonary and systemic arterial pressures, pulmonary vascular resistance, pulmonary blood flow, respiratory gas tensions, intrapulmonary shunt, and S D of pulmonary blood flow, an index of ventilation perfusion mismatching, were measured. Systemic and pulmonary arterial levels of thromboxane B2 and 6-keto-PGF,, were also measured. The sham-treated animals showed the expected rise in pulmonary arterial pressure from 12 f 3 to 29 + 7 torr, (p < 0.02). By comparison, the animals pretreated with DAZ did not demonstrate pulmonary arterial hypertension and had a delay in the fall in pulmonary blood flow until 2 h postinfusion. Arterial PO2 did not decline significantly after the GBS infusion in the DAZ-pretreated animals; the untreated animals showed a significant fall in p 0 2 from baseline. There was no significant change in intrapulmonary shunt or SD of pulmonary blood flow compared to baseline in the DAZ-pretreated animals. The elevation in thromboxane B2 occurring with GBS sepsis did not occur in the DAZ-pretreated animals. We conclude that TxA2 in part mediates the immediate gas exchange and pulmonary hemodynamic abnormalities during GBS sepsis. Inhibition of TxA2 synthetase results in preservation of normal pulmonary gas exchange and a delay in the fall in Q,following GBS infusion. (Pediatr Res 20: 481-486, 1986) Abbreviations GBS, group B streptococci Qs, systemic blood flow SDQ, SD of pulmonary blood flow TxB2, thromboxane B2 PG12, prostacyclin RIA, radioimmunoassay PGE,, prostaglandin El PGFI,, prostaglandin F,, PGE2, prostaglandin E2 DAZ, dazmegrel Hypoxemia develops during an intravenous infusion of GBS in experimental animals (1, 2), indicating a direct or indirect alteration in pulmonary gas exchange as a result of the bacterial sepsis. Mechanisms that might contribute to hypoxemia under these conditions include a reduction in mixed venous pOZ associated with reduced Qs, assuming unchanging tissue oxygen extraction and the presence of some degree of ventilation-perfusion mismatching, or an alteration in the distribution of Q,.
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Altered distribution of Q, may result in substantial perfusion of lung areas receiving no ventilation (shunt), orJung areas receiving little ventilation, i.e. areas with low VA/Q ratios. Both can contribute to hypoxemia depending on extent of diversion of Q, to these areas. We have shown previously in a neonatal piglet model of .GBS sepsis that hypoxemia develops because of both reduced Q, and mismatching of alveolar VA/Q producing an increase in flow to poorly ventilated lung regions, without a significant increase in intrapulmonary shunt (2) .
Others have demonstrated that the vasoconstrictor prostaglandin metabolite, TxA,, mediates the rise in pulmonary arterial pressure, which also occurs during the initial phase of GBS sepsis (1, 3). Piglets treated with the cyclooxygenase inhibitor, indomethacin, have not shown GBS-induced pulmonary hypertension (1). Based on these findings, the present study was designed to test the possibility that blocking the rise in pulmonary arterial pressure with a specific inhibitor of thromboxane synthetase would also inhibit the development of.hypoxemia in a septic newborn piglet by preventing the fall in Q, and the development of VA/Q mismatching. Animal preparation. Eighteen piglets, age 10 to 16 days, were obtained and prepared as previously described (2) . The animals TxA2, thromboxane A2
were anesthetized with pentobarbital, 25 mg/kg intravenously, venous catheters were placed, one for infusion of inert gas solution, the other for infusion of live GBS. Rectal temperature was monitored continuously and maintained at 38 + 0.5" C.
Minute ventilation was calculated by multiplying the tidal volume, as measured by the hot wire anomometer (4) placed in the expired gas stream, by the frequency of ventilator breaths. Total Q, was determined by the thermodilution technique (Edwards 5 10 C.O. computer) using 2-ml samples of 5% dextrose in water at 0" C with measurements made in triplicate or quadruplicate if a greater that 10% discrepancy occurred in the first three samplings (5) . Stroke volume was calculated by dividing Q, by heart rate. An index of pulmonary vascular resistance was calculated according to the formula PVR = (P,, -P,,)/Q, where P,, = mean pulmonary arterial pressure, PC,, = mean pulmonary capillary wedge pressure, and Q, = total pulmonary blood flow. An index of systemic vascular resistance was calculated by dividing mean systemic arterial pressure by Q,, assuming Q, = Q,.
Arterial and mixed venous blood gas tensions and pH were measured within 3 min of blood sampling on a Corning 165 blood gas analyzer. Results were corrected to the animal's temperature.
Assessment of ventilation pevfusion matching. The multiple inert gas elimination technique (6) was employed to assess intrapulmonary shunt and distribution of VA/Q ratios. This technique has been modified, as previously described, for use in small animals (7, 8) . Data derived from the analysis of each of the six inert gases in the pulmonary and systemic arterial blood and mixed expired gases included intrapulmonary shunt and SDQ,. The latter is a unitless index of overall ventilation-perfusion heterogeneity, separate from shunt and dead space (9, 10).
Bacterial preparation. Group B P-hemolytic streptococci (type 111) were inoculated into Todd Hewitt broth and incubated at 32" C for 18 h prior to each experiment. The broth culture was centrifuged at 4 x g at 3" C for 30 min. The bacterial pellet was resuspended in 10 ml phosphate-buffered saline. Bacterial concentration of the resuspended solution was determined by measurement of the optical density with comparison to a previously determined plot of bacterial colony forming units to optical density.
Assessment of prostaglandin metabolites. Four times during the protocol 2-ml blood samples were obtained simultaneously from the systemic arterial and pulmonary arterial circulation. The blood was drawn into an inhibitor solution of 0.6 mg indomethacin and 2 mg of sodium EDTA per ml of blood. The inhibitor solution and the inhibitor-blood mixture were kept in an ice bath until centrifugation at 15,000 rpm for 10 min in a refrigerated centrifuge. The decanted fluid was promptly frozen and stored at -70" C until analysis. Assays for TxB2, the stable metabolite of TxA2, and 6-keto-PGF],, the stable metabolite of prostacyclin, were measured by Dr. John Harlan, Department of Medicine, University of Washington, Seattle, WA. The RIA for TxB2 used a commercially available kit (New England Nuclear, Boston, MA). The level of sensitivity was 10 pg/100 p1 of sample. The RIA for 6-keto-PGF,, used a locally prepared antibody; sensitivity level was 10 pg 1300 p1 of sample. Crossreactivity of the 6-keto-PGF1, antibody at a normalized percent bound of 50% was PGF,,, < 7.8%; PGE,, < 3%; PGF2,, < 2.7%; PGE2, < 2%; prostaglandin A,, < 0.3%; prostaglandin A2, < 0.1 %; TxB2, < 0.1 %; and 13,14-dihydro-15 keto-PGF,,, < 0.02% (New England Nuclear Technical Bulletin HEK-008). Crossreactivity of the TxB2 antibody at normalized bound of 50% was PGE2 < 0.2%, PGA2 < 0.2%, PGF2 < 0.2%, and 6-keto-PGF,, < 0.2% (New England Nuclear Technical Bulletin NEK-007)
(1 1, 12). The TxB2 and 6-keto-PGF], levels were determined by direct assay of anesthetized piglet plasma. Matrix effects due to protein present in unknown piglet plasma samples were determined in standard curves run in eicosnoid free piglet plasma prepared as previously described (12) . Samples were analyzed in duplicate and the values for the 6-keto-PGF,, and TxB2 are expressed as the average of the two values obtained with each analysis.
Experimental protocol. Figure 1 depicts the experimental protocol. Following collection of a baseline set of data, the animals were randomized to receive 8 mg/kg DAZ (UK 38, 485, kindly supplied by Dr. R. Urguilla, Pfizer Laboratories, Groton, CT) or the camer solution for DAZ. The powder form of DAZ was dissolved in 1 ml 0.1 N NaOH to which 0.9% saline was added to make 5 ml of solution. This mixture was infused in each of the treated animals over a 5-min period. Sham-treated animals received the same NaOH-saline solution without the DAZ.
Thirty minutes following the drug treatment, a second set of samples was obtained to determine any hemodynamic effects of the DAZ in the piglets. Following these measurements, an infusion of 2 x lo9 colony forming units/kg of GBS was administered over 30 min. Twenty minutes into the infusion of bacteria, a third set of samples was obtained. Finally, at 1 h (and 2 h in the DAZ-treated group) sample 4 (and 5) were obtained. Measurement of Q,, P, , PVR, respiratory gas tensions, pH, and systemic arterial pressure was made each of the sampling periods. Analysis of prostaglandin metabolites was performed for sampling periods 1 through 4. Inert gas data were obtained at sampling times 1 through 5 in the DAZ pretreated animals but not the control animals. Inert gas data from a previously studied set of control animals (2) maneuver indicated statistical significance, then the paired t test was used for intragroup comparisons and the unpaired t test was used for intergroup comparisons. A p value of <0.02 was considered significant to minimize the effects of multiple comparisons of the paired data with baseline measurements, when the baseline measurement was compared to three postbaseline sampling points. The nonparametric Mann Whitney U test was used for analysis of inert gas data (1 3).
RESULTS
The two groups of piglets were well matched for weight at the time of study (DAZ = 3.1 f 0.5 kg and control = 3.2 f 0.6 kg) and did not differ significantly in any of the baseline measurements. All animals were free of bacterial sepsis at the start of the experiment, based on blood cultures obtained at that time. Figure 2 illustrates the changes in pulmonary arterial pressure between the two groups. DAZ administration had no effect on pulmonary arterial pressure prior to the onset of the GBS infusion. The rise in P,, previously reported in experimental GBS sepsis occurred in the sham treated group but was blunted in the TlME , HRS. treated group occurred at 20 min after the infusion reconfirming previous observations (1, 2). There was no change in Q, in the DAZ treated group. at 20 min, but by 2 h after the end of the bacterial infusion, Q, had fallen equally in the DAZ-treated and control groups. Figure 4 illustrates the calculated pulmonary vascular resistance. The immediate large increase in PVR at 20 min in the sham-treated group did not occur in the DAZ-treated group. However, by 1 h following the end of the GBS infusion, PVR in both groups was not significantly different, as there had been a small rise in PVR in the DAZ-treated group. Figure 5 illustrates changes in arterial oxygen tension during the experiment. The DAZ-treated group did not show a significant fall from baseline in arterial oxygen tension during or following the bacterial infusion. In contrast, the arterial p 0 2 declined ( p < 0.02) from the mean baseline value during the infusion of GBS, and remained depressed thereafter.
Figures 6A and B demonstrate the effects of DAZ on inert gas exchange in septic piglets. There was no significant change, compared to baseline data,.in intrapulmonary shunt, or in the magnitude of the low VA/Q areas during GBS infusion in the animals pretreated with DAZ. Previously reported results for --S D Q~ (2) in non-DAZ treated animals showed a significant increase in SDQ,. These data are shown for comparison in Figures 6A and B . Figures 7A and B illustrate the results of the prostaglandin metabolite measurements in plasma sampled from the systemic artery. Figure 7A demonstrates the significant rise in arterial TxB2 levels during and following GBS infusion in the sham pretreated animals. There was no rise in TxB, with the DAZpretreated animals. Figure 7B illustrates a small, statistically insignificant increase in 6-keto-PGFI, in the DAZ-treated group. In the sham-treated group, there was also no significant rise. For both TxB, and 6-keto-PGFI,, the systemic arterial values were approximately 20% higher in all cases than the values obtained from plasma drawn from the pulmonary artery. Figure 8 illustrates the significant correlation between TxB2 and calculated pulmonary vascular resistance for all animals at any point during the experiment. Table 1 shows values for mean systemic arterial pressure, systemic vascular resistance, calculated stroke volume, and heart rate. The immediate rise in systemic vascular resistance with GBS infusion found in the sham-treated group was delayed in the DAZ-treated group. The immediate decline in stroke volume Others have also utilized substances known to block pathways with GBS infusion was delayed until 2 h post-GBS infusion in the DAZ-treated group.
Neither mixed venous oxygen tension nor pulmonary capillary wedge pressure was significantly different from baseline at any experimental point in the two groups.
DISCUSSION
The results of this study demonstrate that pretreatment of neonatal piglets with DAZ, a thromboxane synthetase inhibitor, blocks the immediate rise in P,,, blunts the decline in PaO,, and delays the decline in Q,, stroke volume, and the rise in SVR which accompany the intravenous infusion of GBS. Pulmonary gas exchange abnormalities, noted in previously studied septic piglets using the inert gas elimination technique (2), were inhibited by pretreatment with DAZ. Finally, this study demonstrates that DAZ blocks the expected rise in circulating levels of TxB,, the stable metabolite of the vasoconstrictor substance TxA2. TlME HRS.
T I M E , HRS
*I DAZ 0 = SHAM TlME , HRS. Fig. 7 .A, plots levels of TxB2 expressed in ng/ml. Sham-treated animals showed a rise in TxB2 levels from baseline conditions at 20 min into the infusion of bacteria and at 1 h following infusion ( p < 0.02).
There was no significant change in the mean levels in the DAZ-pretreated animals. ** = p < 0.02. B illustrates 6-keto-PGF,,levels expressed in ng/ ml. No significant rise was detected in the sham or DAZ-treated animals. (1 2) also utilized dazoxiben in a goat model and suppressed the elevation in P,,. However, they demonstrated a greater fall in arterial PO2 in the animals pretreated with dazoxiben than in untreated animals prior to infusion of the endotoxin. These results (12) raised questions as to the importance of the changes in pulmonary hemodynamics as a regulator of gas exchange. In Our results are consistent with those of Farmkh el al. (16) who demonstrated that TxA2 was the dominant mediator of pulmonary hypertension induced by arachidonic acid or lipid infusion into an isolated lobe preparation. The present results are the first in neonatal animals to use the substance DAZ. This experimental substance appears to be a more specific blocker of TxA2 synthesis than dazoxiben (17) . Utilizing a specific TxA2 synthetase inhibitor should minimize the potential increase in synthesis of other prostaglandin metabolites from increased activity of a different pathway when one metabolic pathway is blocked. For example, inhibition of leukotriene synthesis with diethylcarbamazine has been associated with increased production of PG12 synthesis (18) . Similarly, blockage of the cyclooxygenase pathway may stimulate increased production of leukotrienes, themselves potent vaso-and bronchoconstrictors (19) . The findings in our experiment of an insignificant rise in PG12 with DAZ pretreatment suggests that there was no or minimal increased production of this metabolite. This result contrasts with the results of Runkle el a/. ( I ) in which a more substantial increase in 6-keto-PGF,, was detected. The correlation between TxA2 and PVR (Fig. 8) supports the thesis that TxA2 is a major mediator of pulmonary vascular constriction induced by live bacteria or endotoxin.
Our results also demonstrate an association between blocking the acute elevation in PVR and the fall in Q,, and regulation of pulmonary gas exchange. Others have found that acute reversal of preexisting pulmonary hypertension may result in impaired gas exchange because of an increase in shunt or low VA/Q lung regions (20, 2 1) . The present results are consistent with previous experimental findings that moderate degrees of .pulmonary hypertension do not predispose to deterioration of VA/Q matching, but more extreme elevations of P,,, at least in newbom animals, may be associated with increased shunt or increased VA/Q mismatching (22) . The effect of DAZ in preventing a decline in p 0 2 may be brief in duration. By 1 h post-GBS infusion, there was no statistical difference in mean arterial p02 between the two groups.
The acute fall in stroke volume in the sham-treated animals may have occurred because of the concomitant rise in SVR, or because of decreased myocardial contractility. The delay in the rise in afterload, as measured by SVR, in the DAZ-treated animals suggests that release of TxA2 may only partially mediate elevations in SVR and other factors also regulate systemic vasoconstriction.
The present results suggest a relationship between alterations in pulmonary arterial pressure and pulmonary gas exchange. We speculate that extreme rises in pulmonary arterial pressure in neonates may inhibit the mechanisms preserving efficient pulmonary gas exchange. To the extent that this disruption contributes to the pathophysiology of early onset GBS sepsis, then DAZ, or similar substances, may play a role in the therapy of this highly lethal disease. This speculation is consistent with results using indomethacin or ibuprofen as a cyclooxygenase inhibitor in a different model of GBS sepsis (23) . Further experimental work assessing the effects of DAZ administration at the time of, or even following, the acute effects of GBS infusion will support or refute this speculation.
